Status:
UNKNOWN
Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy
Lead Sponsor:
Taipei Veterans General Hospital, Taiwan
Conditions:
Diabetes
Eligibility:
All Genders
30-80 years
Phase:
PHASE4
Brief Summary
Objectives: Thiazolidinediones (TZDs) are insulin sensitizers that decrease plasma glucose in type 2 diabetic patients. Thiazolidinediones can cause fluid retention and peripheral edema in diabetic p...
Detailed Description
The effects of thiazolidinedione on the diabetic retinopathy and nephropathy: Overall Goal and Specific Aims The overall goal of this study is to examine the effects of thiazolidinediones on the dia...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Age between 30-80 years old
- No significant nephropathy
- No significant retinopathy
- On submaximal dose of sulphonylureas and metformin treatment
- A1C between 7-9%
Exclusion
- On insulin treatment
- Significant retinopathy (greater than moderate non-proliferative retinopathy)
- Significant nephropathy (overt proteinuria or serum Cr \>1.50 mg/dL)
- Malignancy
- Pregnancy
- Acute intercurrent illness
- Congestive heart failure (CHF, according to New York heart Association, NYHA functional class III to IV)
- Myocardial infarction, received PCI or CABG or liver cirrhosis
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2015
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01175486
Start Date
July 1 2010
End Date
December 1 2015
Last Update
January 5 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei Veterans General Hospital, Taiwan
Taipei, Taiwan